A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

• Published in: International journal of infectious diseases Vol. 30; no. C; pp. 67 - 73
• Main Authors: O’Riordan, William, Mehra, Purvi, Manos, Paul, Kingsley, Jeff, Lawrence, Laura, Cammarata, Sue
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.01.2015; Elsevier
• Subjects: Abscess - drug therapy; ABSSSIs; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Cellulitis - drug therapy; Delafloxacin; Double-Blind Method; Female; Fluoroquinolones - administration & dosage; Fluoroquinolones - adverse effects; Fluoroquinolones - therapeutic use; Humans; Infectious Disease; Male; Middle Aged; Minocycline - analogs & derivatives; Minocycline - therapeutic use; MRSA; MSSA; Polymicrobial skin infections; Pulmonary/Respiratory; Wound Infection - drug therapy; Young Adult; MSSA; ABSSSIs; Delafloxacin; Polymicrobial skin infections; MRSA
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2014.10.009

Highlights • Complicated skin and skin-structure infections (cSSSIs) may require surgery. • A study of the efficacy and safety of two doses of delafloxacin vs. tigecycline in cSSSIs was performed. • Patients were randomized by infection type: abscess, wound infection, or cellulitis. • Both delafloxacin and tigecycline had cure rates >90% for all pathogens/infections. • Delafloxacin was well tolerated at a dose of 300 mg intravenous every 12 h.